Substance-Related and Addictive Disorders

What Are Substance-Related and Addictive Disorders?

Substance-related and addictive disorders describe a cluster of conditions in which repeated use of a substance, or engagement in a specific behavior, overrides a person’s ability to control that use despite clear harm to health, relationships, and daily functioning. The category sits inside the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, where it replaced the older, looser terms substance abuse and substance dependence with a single, measurable diagnosis on a severity spectrum.

According to the American Psychiatric Association, addiction is a complex condition in which a person engages in compulsive use of a substance despite harmful consequences, and brain changes that occur over time challenge a person’s self-control and interfere with their ability to resist intense urges. This definition captures the core feature of every disorder in this chapter: control has been lost, and the loss is not simply a matter of willpower.

Ten separate classes of drugs fall under this diagnostic umbrella, alongside one behavioral condition, gambling disorder, which is included because research shows it activates the same reward circuitry as chemical substances. Students preparing a psychology case study on this topic should understand that the category is unusually broad, spanning everything from nicotine dependence to severe opioid use disorder, and that severity, not the specific substance, drives most of the clinical decision-making.

Why Did the DSM-5 Merge Abuse and Dependence?

Earlier editions of the DSM separated substance abuse, a milder pattern of harmful use, from substance dependence, a more severe pattern marked by tolerance and withdrawal. Field research ahead of the DSM-5 revision found that this split did not match how the disorder actually behaved clinically. The National Institute on Drug Abuse notes that abuse and dependence symptoms did not sort cleanly into two categories, and many patients showed a mixture of both, which pointed toward a single underlying continuum rather than two separate conditions.

The result was substance use disorder, a unified diagnosis graded as mild, moderate, or severe based on how many of eleven criteria a person meets. This change matters enormously for how clinicians, researchers, and insurers talk about the condition, and it is one of the most frequently tested distinctions in abnormal psychology courses. If your assignment requires tracing this diagnostic evolution, literature review guidance can help you build a clear historical argument from DSM-IV to DSM-5.

What Makes a Behavior “Addictive” Rather Than Just Habitual?

Not every repeated behavior qualifies as an addictive disorder. The clinical threshold requires impaired control, continued use despite harm, and a physiological or psychological compulsion that overrides ordinary decision-making. A person who drinks coffee daily is not exhibiting an addictive disorder in the clinical sense, because caffeine use rarely produces the social, occupational, or health impairment required for diagnosis. Addiction, by contrast, reshapes priorities so completely that obtaining and using the substance becomes the organizing activity of a person’s life.

The 11 DSM-5 Diagnostic Criteria for Substance Use Disorder

The DSM-5 organizes its eleven diagnostic criteria for substance use disorder into four conceptual groups: impaired control, social impairment, risky use, and pharmacological indicators. A clinician evaluates whether a patient has met two or more of these criteria within a twelve-month period, and the total count determines the severity specifier attached to the diagnosis.

Group 1: Impaired Control (Criteria 1–4)

This group covers using more of the substance than intended, unsuccessful efforts to cut down, spending excessive time obtaining or recovering from the substance, and experiencing intense cravings. Craving was added as a new criterion in the DSM-5 specifically because the Substance Abuse and Mental Health Services Administration and other bodies recognized it as one of the strongest predictors of relapse.

Group 2: Social Impairment (Criteria 5–7)

These criteria assess whether substance use has caused a person to fail major role obligations at work, school, or home, whether use continues despite recurring social or interpersonal problems, and whether important social, occupational, or recreational activities have been given up because of use.

Group 3: Risky Use (Criteria 8–9)

This group captures recurrent use in physically hazardous situations, such as driving while intoxicated, and continued use despite knowing it is causing or worsening a physical or psychological problem.

Group 4: Pharmacological Criteria (Criteria 10–11)

The final two criteria are tolerance, needing markedly increased amounts of the substance to achieve the same effect, and withdrawal, experiencing a characteristic syndrome when the substance is discontinued. Notably, the DSM-5 specifies that tolerance and withdrawal alone, in the context of appropriately prescribed medication, do not automatically indicate a substance use disorder, which matters for patients on legitimate pain or anxiety management regimens.

How Do Clinicians Apply These Criteria in Practice?

A diagnostic interview typically walks through each of the eleven criteria systematically, asking about the past twelve months of use. Structured tools such as the Alcohol Use Disorders Identification Test and the Drug Abuse Screening Test are frequently used alongside the clinical interview to standardize this process. For nursing and psychology students building an mental health nursing assessment, understanding how these criteria translate into an actual patient interview is essential preparation for clinical placements.

It is worth noting that the number of criteria met does not always map neatly onto how outside observers perceive the severity of a person’s condition. Someone who meets only two or three criteria can still experience serious personal distress, which is why clinicians pair the criteria count with a broader functional assessment rather than relying on the number alone.

The Ten Classes of Substances Recognized by the DSM-5

The DSM-5 groups substance-related disorders around ten distinct pharmacological classes. Each class produces its own characteristic intoxication and withdrawal profile, even though all ten share the same eleven-criteria diagnostic structure for substance use disorder. Recognizing each class, not just memorizing the list, is central to any comprehensive academic treatment of this topic.

Alcohol

Alcohol use disorder is among the most extensively studied conditions in this chapter and one of the leading preventable causes of death in the United States. The National Institute on Alcohol Abuse and Alcoholism reports that alcohol use disorder affects millions of adults annually and is associated with liver disease, cardiovascular damage, and a wide range of psychiatric complications. Alcohol withdrawal can be medically dangerous, occasionally producing seizures or delirium tremens, which is why abrupt cessation in severe cases requires supervised medical detoxification.

Caffeine

Caffeine is unique in this chapter because the DSM-5 recognizes caffeine intoxication and caffeine withdrawal but does not include a formal caffeine use disorder diagnosis, citing insufficient evidence that typical caffeine use produces the same level of functional impairment seen with other substances. It remains a condition proposed for further study.

Cannabis

Cannabis use disorder has drawn increasing clinical attention as legalization has expanded across many U.S. states and parts of the UK medical system. Regular high-potency use is linked to cannabis withdrawal syndrome, characterized by irritability, sleep disturbance, and decreased appetite, alongside broader concerns about cognitive effects with heavy adolescent use.

Hallucinogens

This class includes phencyclidine and other hallucinogens such as LSD and psilocybin. The DSM-5 notes that classic hallucinogens do not typically produce a defined withdrawal syndrome, which distinguishes this class pharmacologically from most others in the chapter, even though compulsive patterns of use and hallucinogen persisting perception disorder remain clinically significant.

Inhalants

Inhalant use disorder involves substances such as solvents, aerosols, and glues used specifically for their intoxicating effects. This class is clinically important because it disproportionately affects younger adolescents due to the accessibility and low cost of inhalant products, and it carries a meaningful risk of sudden cardiac events even on first use.

Opioids

Opioid use disorder has become one of the most urgent public health concerns in the United States, driven by prescription painkillers, heroin, and increasingly potent synthetic opioids such as fentanyl. The National Institute on Drug Abuse documents that opioid overdose deaths rose sharply over the past decade, prompting expanded access to medication-assisted treatment and overdose-reversal medications such as naloxone.

Sedatives, Hypnotics, and Anxiolytics

This class covers benzodiazepines, barbiturates, and related prescription medications used for anxiety and sleep. Because these drugs are frequently prescribed legitimately, distinguishing appropriate medical use from a diagnosable use disorder requires careful clinical judgment, particularly regarding the tolerance and withdrawal criteria.

Stimulants

Stimulant use disorder covers cocaine, amphetamines, and related compounds, including misused prescription stimulants such as those prescribed for ADHD. Stimulant intoxication produces euphoria and heightened alertness, while withdrawal is marked by fatigue, low mood, and increased appetite, sometimes described clinically as a “crash.”

Tobacco

Tobacco use disorder, driven primarily by nicotine, remains the leading cause of preventable death in both the United States and United Kingdom according to public health data from the Centers for Disease Control and Prevention. Nicotine’s addictive profile, including rapid tolerance and a distinct withdrawal syndrome, makes it one of the most extensively researched substances in the entire DSM-5 chapter.

Other or Unknown Substances

The DSM-5 includes a residual category for substances that do not fit clearly into the other nine classes, including anabolic steroids, over-the-counter medications used non-medically, and novel psychoactive substances that emerge faster than formal classification systems can track them.

Understanding this table is often the first step toward writing a strong case analysis essay in an abnormal psychology or pharmacology course, since instructors frequently ask students to compare intoxication and withdrawal profiles across substance classes.

Gambling Disorder: The Non-Substance Addictive Disorder

Gambling disorder is the only behavioral condition included in the DSM-5 Substance-Related and Addictive Disorders chapter, a placement that reflects a major shift in how the field understands addiction. Earlier editions classified problem gambling as an impulse-control disorder, grouped alongside conditions like kleptomania. The DSM-5 reclassified it after neuroimaging research showed that gambling activates the brain’s reward circuitry in ways strikingly similar to substance use.

Diagnosis requires that a person exhibit persistent and recurrent problematic gambling behavior leading to clinically significant impairment, evidenced by at least four of nine specified criteria within a twelve-month period. These include needing to gamble with increasing amounts of money to achieve excitement, restlessness when attempting to cut down, repeated unsuccessful efforts to control gambling, and relying on others to relieve financial problems caused by gambling.

Why Was Gambling Reclassified as an Addiction?

The reclassification rested on converging evidence from brain imaging, genetics, and treatment response. People with gambling disorder show altered activity in the ventral striatum and prefrontal cortex, the same regions implicated in substance addiction. They also frequently show tolerance-like patterns, needing larger bets to achieve the same emotional high, and withdrawal-like symptoms, including irritability and anxiety when unable to gamble.

Are Other Behaviors Being Considered for This Category?

Internet gaming disorder currently appears in the DSM-5 as a condition recommended for further research rather than a formal diagnosis, reflecting ongoing debate about whether excessive gaming meets the same threshold of neurobiological and functional impairment as gambling disorder. The World Health Organization has taken a different position, formally recognizing gaming disorder in the ICD-11 classification system, which creates an interesting point of comparison for students studying cross-national diagnostic frameworks.

The Neurobiology of Addiction: What Happens in the Brain

Understanding addiction as a brain disease is the central conceptual shift that separates modern addiction science from older moral-failing models of substance use. According to NIDA’s Science of Addiction resource, drugs act on the brain’s reward circuit by flooding it with dopamine, a neurotransmitter that regulates movement, emotion, motivation, and feelings of pleasure. This flood reinforces the drug-taking behavior, teaching the brain to repeat it.

The Reward Circuit and the Role of Dopamine

The mesolimbic dopamine pathway, running from the ventral tegmental area to the nucleus accumbens, is the brain’s primary reward circuit. Natural rewards such as food and social connection trigger modest dopamine release along this pathway. Addictive substances trigger a dopamine surge far larger than any natural reward, which is why the brain begins to prioritize the substance over activities that once brought ordinary satisfaction.

Tolerance and the Brain’s Adaptation

With repeated exposure, the brain adapts by reducing its own dopamine production and receptor sensitivity, a process called neuroadaptation. This is the biological basis of tolerance, needing more of the substance to achieve the same effect, and it also explains why activities that once felt rewarding become dull without the substance, a state researchers call anhedonia.

Nora Volkow and the Modern Addiction Model

Dr. Nora Volkow, Director of the National Institute on Drug Abuse, has been one of the most influential figures in reframing addiction as a disorder of brain circuitry rather than a character flaw. Her research using positron emission tomography imaging demonstrated measurable reductions in dopamine receptor availability among people with substance use disorders, providing some of the clearest physical evidence that addiction produces lasting, observable brain changes.

The Prefrontal Cortex and Loss of Control

Addiction does not only affect the reward circuit. Chronic substance use also impairs the prefrontal cortex, the brain region responsible for judgment, decision-making, and impulse control. This dual impact, heightened reward-seeking paired with weakened self-regulation, explains why willpower alone is rarely sufficient to overcome a severe substance use disorder, and why relapse is considered a common and expected part of the recovery process rather than a moral failure.

Risk Factors for Substance-Related and Addictive Disorders

No single cause explains why one person develops a substance use disorder while another does not. Research consistently points to an interaction between genetic vulnerability, environmental exposure, and developmental timing, often summarized as the biopsychosocial model of addiction.

Genetic and Biological Factors

Twin and adoption studies estimate that genetic factors account for roughly forty to sixty percent of a person’s vulnerability to addiction, according to research summarized by NIDA. Genes influence how strongly a substance activates the reward circuit, how quickly tolerance develops, and how uncomfortable withdrawal feels, all of which shape the likelihood of continued use.

Environmental and Social Factors

Early exposure to substance use within the family, peer pressure, community norms, and socioeconomic stress all meaningfully raise risk. Adverse childhood experiences, including trauma, neglect, and household dysfunction, are among the most robust predictors identified in longitudinal research, with each additional adverse experience increasing the statistical likelihood of later substance use disorder.

Developmental Timing: Why Adolescence Matters

The adolescent brain is still developing its prefrontal cortex, the region responsible for impulse control and long-term planning, well into the mid-twenties. Substance exposure during this window is disproportionately likely to produce lasting changes in reward sensitivity, which is why early-onset use is one of the strongest predictors of a severe substance use disorder in adulthood.

Psychological and Personality Factors

Traits such as high impulsivity, sensation-seeking, and difficulty regulating negative emotion are consistently linked to elevated risk. Many individuals also report using substances to self-medicate underlying anxiety, depression, or trauma symptoms, a pattern that connects directly to the dual diagnosis considerations discussed later in this guide. Students exploring these psychological dimensions may find it useful to review introduction to biological psychology materials for background on temperament and neurochemistry.

Intoxication and Withdrawal: What’s the Difference?

Beyond the substance use disorder diagnosis itself, the DSM-5 recognizes separate diagnoses for substance intoxication and substance withdrawal for most substance classes. These conditions can occur independently of a full use disorder diagnosis, and distinguishing them correctly is a frequently tested skill in clinical and academic settings.

Substance Intoxication

Intoxication refers to a reversible, substance-specific syndrome that develops during or shortly after use of a substance, caused by its direct effect on the central nervous system. Symptoms vary widely by class, ranging from the sedation and slowed reaction time of alcohol intoxication to the elevated heart rate and euphoria of stimulant intoxication. A single episode of intoxication does not by itself indicate a use disorder.

Substance Withdrawal

Withdrawal describes a substance-specific syndrome that develops when a person who has used a substance heavily and for a prolonged period stops or reduces use. Symptoms are frequently the physiological opposite of intoxication effects, and severity ranges from mild discomfort, as with caffeine withdrawal headaches, to medically dangerous, as with alcohol or benzodiazepine withdrawal, which can produce seizures and requires careful medical supervision.

Why This Distinction Matters Clinically

Confusing intoxication with withdrawal, or assuming either automatically confirms a use disorder, is one of the most common errors in student case analyses. A patient in a hospital setting receiving opioids for legitimate post-surgical pain management may show tolerance and even mild withdrawal symptoms upon dose reduction without meeting criteria for opioid use disorder, because the DSM-5 explicitly excludes these two criteria when substances are used exactly as prescribed under medical supervision.

For students preparing quantitative comparisons of these syndromes, reviewing qualitative versus quantitative data methods can help structure a rigorous symptom-comparison table for a research paper or clinical case presentation.

Dual Diagnosis: Substance Use and Co-Occurring Mental Illness

Dual diagnosis, also called co-occurring disorders, describes the presence of both a substance-related disorder and another mental health condition in the same individual. This overlap is far from rare. SAMHSA reports that millions of U.S. adults experience both a substance use disorder and a mental illness in a given year, and treating one condition while ignoring the other consistently produces worse outcomes than integrated care.

Common Co-Occurring Conditions

Depression, anxiety disorders, post-traumatic stress disorder, and bipolar disorder are among the conditions most frequently seen alongside substance use disorders. The relationship runs in multiple directions: some individuals use substances to self-medicate distressing psychiatric symptoms, some substances directly trigger or worsen psychiatric symptoms, and shared genetic and environmental risk factors can produce both conditions independently.

Why Integrated Treatment Matters

Historically, mental health and addiction treatment operated in separate, poorly coordinated systems, forcing patients to be “stable” in one domain before receiving care in the other. Modern best practice favors integrated treatment, addressing both conditions simultaneously within the same care team, which research consistently shows produces better retention and outcomes than sequential or parallel treatment models.

Nursing students working through perspectives on health and well-being in nursing assignments often encounter dual diagnosis as a core case study topic, since it requires coordinating pharmacological, psychological, and social interventions simultaneously.

Key Organizations and Researchers in Addiction Science

Addiction science is anchored by specific institutions and researchers whose work defines how the field measures, treats, and talks about substance-related disorders. Referencing these entities accurately gives academic writing on this topic real credibility and depth.

National Institute on Drug Abuse (NIDA)

NIDA, part of the U.S. National Institutes of Health, funds the majority of the world’s research on the health effects of drug use and addiction. Its resources, including the widely cited publication Drugs, Brains, and Behavior: The Science of Addiction, are among the most frequently referenced sources in academic writing on this topic.

Substance Abuse and Mental Health Services Administration (SAMHSA)

SAMHSA is the U.S. federal agency responsible for advancing behavioral health, and it conducts the annual National Survey on Drug Use and Health, the primary data source for national substance use prevalence statistics cited throughout this article and across the field.

American Psychiatric Association (APA)

The APA publishes and periodically revises the DSM itself, making it the authoritative body behind every diagnostic criterion discussed in this guide. Its public-facing resources on addiction are a reliable, citable source for definitional and diagnostic questions.

American Society of Addiction Medicine (ASAM)

ASAM is the leading U.S. medical society dedicated to addiction medicine, and its formal definition of addiction as a treatable, chronic medical disease has become the standard reference point cited across clinical and academic addiction literature.

World Health Organization (WHO)

The WHO maintains the International Classification of Diseases, currently in its eleventh revision, which provides the global diagnostic framework used alongside the DSM-5, particularly relevant for UK and international clinical settings governed by ICD rather than DSM criteria.

National Health Service (NHS), United Kingdom

The NHS provides publicly funded addiction treatment services across the UK, including specialist alcohol and drug services, and its clinical guidance documents offer a useful point of comparison against U.S. treatment models for students writing cross-national policy analyses.

Dr. Nora Volkow

As discussed earlier, Dr. Volkow’s neuroimaging research has been central to establishing addiction’s biological basis, and her name appears consistently across contemporary addiction neuroscience literature.

Evidence-Based Treatment Approaches

Treatment for substance-related and addictive disorders is rarely a single intervention. Most effective care plans combine medical, psychological, and social support components tailored to the substance involved, the severity of the disorder, and any co-occurring conditions.

For students writing an intervention-focused paper, the psychotherapy approaches in treating mental disorders guide offers additional structure for comparing therapeutic modalities systematically.

Substance Use Disorders, Policy, and Public Health

Substance-related and addictive disorders sit at the intersection of clinical medicine and public policy, shaping how governments in the United States and United Kingdom allocate healthcare resources, design criminal justice responses, and fund prevention programs.

The Opioid Crisis and Policy Response

The sharp rise in opioid overdose deaths across the United States over the past two decades prompted significant policy shifts, including expanded access to naloxone, prescription drug monitoring programs, and increased funding for medication-assisted treatment. The CDC continues to track overdose trends closely, and this data forms the empirical backbone of most U.S. federal drug policy discussions today.

Harm Reduction Approaches

Harm reduction strategies, including needle exchange programs and supervised consumption sites, aim to reduce the health risks associated with substance use without requiring immediate abstinence. These approaches remain politically contested in both the U.S. and UK, with debate centered on whether they enable continued use or serve as an effective bridge into eventual treatment.

Decriminalization and Treatment-Oriented Justice Models

A growing number of jurisdictions have shifted toward treatment-oriented responses to low-level drug offenses, including drug courts that divert individuals toward treatment rather than incarceration. This reflects broader recognition, informed by the neurobiological evidence discussed earlier, that punitive-only approaches are less effective at reducing recidivism than integrated treatment models. Students analyzing this shift for a political science assignment will find rich material comparing U.S. state-level and UK national policy approaches.

Prevention Programs and Public Health Investment

Prevention research consistently shows that school-based and family-based programs targeting risk and protective factors before adolescence produce meaningful reductions in later substance use disorder rates, making early prevention one of the most cost-effective public health investments available in this domain.

Substance Use Across Life Stages and Demographics in the US and UK

Prevalence and presentation of substance-related and addictive disorders shift considerably across age groups, genders, and regions, and understanding these patterns strengthens both clinical assessment and academic analysis of the topic.

Adolescence and Young Adulthood

Substance use typically begins during adolescence, and the eighteen-to-twenty-five age bracket consistently shows the highest rates of substance use disorder diagnosis in national U.S. survey data. This period overlaps directly with continued prefrontal cortex development, reinforcing why early intervention during these years carries outsized long-term benefit. College environments in particular present a distinctive risk profile, combining increased independence, social pressure, and, for many students, a first sustained period away from parental monitoring.

Middle Adulthood

Among adults in their thirties through fifties, alcohol use disorder and prescription medication misuse, particularly involving sedatives and opioids prescribed for chronic pain, become more prominent clinical concerns. Occupational stress, caregiving burden, and untreated chronic pain are frequently cited contributing factors within this age group.

Older Adults

Substance use disorders in older adults are often under-recognized because symptoms can be mistaken for normal aging, medication interactions, or early cognitive decline. Alcohol and prescription sedative misuse are the most common patterns in this population, and clinicians are increasingly encouraged to screen routinely rather than assume older patients are low risk.

Gender Differences

Historically, substance use disorders have been diagnosed more frequently in men, though the gap has narrowed considerably in recent decades, particularly for alcohol and prescription medication misuse. Women tend to progress from initial use to a diagnosable disorder more rapidly than men for several substances, a pattern researchers refer to as telescoping, and they more frequently report using substances to cope with co-occurring anxiety, depression, or trauma symptoms.

United States and United Kingdom: A Brief Comparison

Both countries report opioids, alcohol, and cannabis among their most clinically significant substance categories, though the specific policy and treatment landscape differs. The United States has faced a particularly severe synthetic opioid crisis driven by fentanyl, prompting significant federal investment in medication-assisted treatment access. The United Kingdom’s NHS-integrated model provides publicly funded specialist alcohol and drug services nationally, offering a useful contrast for students examining how healthcare system structure shapes addiction treatment access and outcomes.

How to Study Substance-Related Disorders for Exams

This topic appears across introductory psychology, abnormal psychology, nursing pharmacology, and public health curricula, and each context tests it slightly differently. Here is how to approach it strategically.

Master the Eleven Criteria Before Anything Else

Nearly every exam question in this domain ultimately traces back to the eleven DSM-5 criteria and their four conceptual groups. Being able to name each group, impaired control, social impairment, risky use, and pharmacological effects, and give an example of each, will carry you through most short-answer and essay questions.

Use Specific Substances, Not Generic Examples

Examiners reward specificity. Rather than writing generically about “drug addiction,” name the substance class, describe its characteristic intoxication and withdrawal profile, and connect it to a specific criterion. This demonstrates genuine comprehension rather than surface-level recall.

Connect Neurobiology to Clinical Presentation

Strong answers link the dopamine reward circuit and prefrontal cortex impairment directly to observable clinical symptoms, such as craving and impaired control, rather than treating neuroscience and diagnosis as separate topics.

Practice Case Study Analysis

Applying the diagnostic framework to a realistic case vignette is the most common assessment format in upper-level courses. Practice identifying which of the eleven criteria a hypothetical patient meets, then determine the correct severity specifier. For structured guidance on building this kind of analysis, psychology case study writing guidance walks through the process step by step.

Frequently Asked Questions About Substance-Related and Addictive Disorders